152_CD
GlaxoSmithKline_NN
Shareholder_NN
return_NN
Merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
Dividends_NN
The_DT
merger_NN
was_VBD [BYPA]
implemented_VBN
by_PIN
way_NN
of_PIN
a_DT
scheme_NN
of_PIN
arrangement_NOMZ
GlaxoSmithKline_NN
pays_VPRT
dividends_NN
quarterly_RB
._.
At_PIN
present_JJ
,_,
it_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
and_PHC
became_VBD
effective_JJ
on_PIN
27th_JJ
December_NN
2000_CD
._.
A_DT
new_JJ
holding_GER
that_DEMO
there_EX
will_PRMD
be_VB
a_DT
level_NN
dividend_NN
for_PIN
each_QUAN
of_PIN
the_DT
first_JJ
three_CD
quarters_NN
,_,
company_NN
,_,
GlaxoSmithKline_NN
plc_NN
,_,
acquired_VBD
Glaxo_NN
Wellcome_NN
and_CC
with_PIN
a_DT
higher_JJ
dividend_NN
in_PIN
the_DT
fourth_JJ
quarter_NN
._.
Each_QUAN
quarters_NN
dividend_NN
SmithKline_NN
Beecham_NN
._.
In_PIN
accordance_NN
with_PIN
the_DT
agreed_VBN [SUAV] [PUBV] [THATD]
merger_NN
is_VPRT [PASS]
announced_VBN [PUBV]
at_PIN
the_DT
time_NN
of_PIN
the_DT
quarterly_JJ
Results_NN
Announcement_NOMZ
._.
terms_NN
,_,
shareholders_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
The_NN
Board_NN
declared_VBD [PUBV]
dividends_NN
for_PIN
2002_CD
as_IN
follows_VPRT
:_:
received_VBN
,_,
in_PIN
exchange_NN
for_PIN
their_TPP3
existing_VBG
shares_NN
,_,
shares_NN
in_PIN
2002_CD
2001_CD
GlaxoSmithKline_NN
as_IN
follows_VPRT
:_:
Dividends_NN
per_PIN
share_NN
pence_NN
pence_NN
First_NN
interim_JJ
-_:
paid_VBN
4th_JJ
July_NN
2002_CD
9_CD
9_CD
for_PIN
each_QUAN
Glaxo_NN
Wellcome_NN
ordinary_JJ
share_NN
1_CD
GlaxoSmithKline_NN
Second_NN
interim_NN
-_:
paid_VBN
3rd_CD
October_NN
2002_CD
9_CD
9_CD
ordinary_JJ
share_NN
Third_JJ
interim_NN
-_:
paid_VBN
3rd_CD
January_NN
2003_CD
9_CD
9_CD
for_PIN
each_QUAN
SmithKline_NN
Beecham_NN
ordinary_JJ
share_NN
0.4552_CD
Fourth_JJ
interim_NN
-_:
payable_JJ
17th_JJ
April_NN
2003_CD
13_CD
12_CD
GlaxoSmithKline_NN
ordinary_JJ
shares_NN
._.
Total_JJ
40_CD
39_CD
In_PIN
the_DT
case_NN
of_PIN
shares_NN
held_VBN [PRIV]
as_IN
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
,_,
holders_NN
of_PIN
Glaxo_NN
Wellcome_NN
ADRs_NN
and_PHC
holders_NN
of_PIN
SmithKline_NN
Dividends_NN
ADSs_NN
Beecham_NN
ADRs_NN
received_VBD
:_:
As_IN
a_DT
guide_NN
to_PIN
holders_NN
of_PIN
ADRs_NN
,_,
the_DT
tables_NN
below_PLACE
set_VBN
out_PIN
the_DT
dividends_NN
for_PIN
each_QUAN
Glaxo_NN
Wellcome_NN
ADS_NN
-_:
1_CD
GlaxoSmithKline_NN
ADS_NN
paid_VBD
per_PIN
ADS_NN
in_PIN
US_FPP1
dollars_NN
in_PIN
the_DT
last_JJ
five_CD
years_NN
._.
The_DT
dividends_NN
are_VPRT [BEMA]
for_PIN
each_QUAN
SmithKline_NN
Beecham_NN
ADS_NN
-_:
1.138_CD
GlaxoSmithKline_NN
ADSs_NN
adjusted_VBN [WZPAST]
for_PIN
UK_NN
tax_NN
credit_NN
less_RB
withholding_VBG
tax_NN
,_,
where_RB
applicable_JJ
,_,
and_ANDC
are_VPRT [PASS]
translated_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
applicable_JJ
exchange_NN
rates_NN
._.
GlaxoSmithKline_NN
shares_NN
commenced_VBD
trading_GER
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
and_PHC
GlaxoSmithKline_NN
ADSs_NN
commenced_VBD
trading_GER
on_PIN
the_DT
Since_OSUB
6th_JJ
April_NN
1999_CD
,_,
claims_VPRT [PUBV]
for_PIN
refunds_NN
of_PIN
tax_NN
credits_NN
on_PIN
dividends_NN
New_NN
York_NN
Stock_NN
Exchange_NN
on_PIN
27th_JJ
December_NN
2000_CD
._.
from_PIN
the_DT
UK_NN
tax_NN
authorities_NOMZ
are_VPRT [BEMA]
of_PIN
negligible_JJ
benefit_NN
to_PIN
US_FPP1
shareholders_NN
._.
Taxation_NOMZ
Year_NN
GSK_NN
$_$
GW_CD
$_$
SB_CD
$_$
General_JJ
information_NOMZ
concerning_VBG [WZPRES]
the_DT
UK_NN
and_PHC
US_FPP1
tax_NN
effects_NN
of_PIN
2002_CD
1.24_CD
share_NN
ownership_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
`_``
Taxation_NOMZ
information_NOMZ
for_PIN
shareholders_NN
'_POS
._.
2001_CD
1.11_CD
2000_CD
1.10_CD
0.87_CD
Share_NN
price_NN
1999_CD
1.14_CD
0.86_CD
2002 2001 2000 1998_CD
1.19_CD
0.81_CD
GSK_NN
GW_NN
SB_NN
Dividends_NN
paid_VBD
to_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
ADR_NN
At_PIN
1st_CD
January_NN
17.23_CD
18.90_CD
17.50_CD
7.90_CD
holders_NN
are_VPRT [PASS]
expressed_VBN
as_IN
dividends_NN
per_PIN
GlaxoSmithKline_NN
ADS_NN
._.
High_NN
during_PIN
the_DT
year_NN
17.80_CD
20.32_CD
21.10_CD
9.55_CD
Low_NN
during_PIN
the_DT
year_NN
10.57_CD
16.26_CD
14.40_CD
6.71_CD
Dividend_NN
calendar_NN
At_PIN
26th_JJ
December_NN
18.42_CD
8.33_CD
At_PIN
31st_CD
December_NN
11.92_CD
17.23_CD
18.90_CD
Fourth_JJ
quarter_NN
2002_CD
Decrease_NN
increase_NN
31_CD
%_NN
9_CD
%_NN
5_CD
%_NN
5_CD
%_NN
Ex-dividend_NN
date_NN
19th_JJ
February_NN
2003_CD
Record_NN
date_NN
21st_CD
February_NN
2003_CD
The_DT
table_NN
above_PLACE
sets_NN
out_PIN
the_DT
middle_JJ
market_NN
closing_GER
prices_NN
derived_VBN
Payable_JJ
17th_JJ
April_NN
2003_CD
from_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
Daily_NN
Official_NN
List_NN
._.
First_JJ
quarter_NN
2003_CD
The_DT
companys_NN
share_VPRT
price_NN
declined_VBD
by_PIN
31_CD
per_PIN
cent_NN
in_PIN
2002_CD
from_PIN
Ex-dividend_NN
date_NN
7th_JJ
May_POMD
2003_CD
a_DT
price_NN
of_PIN
17.23_CD
at_PIN
1st_CD
January_NN
2002_CD
to_PIN
11.92_CD
at_PIN
31st_CD
Record_NN
date_NN
9th_CD
May_POMD
2003_CD
December_NN
2002_CD
._.
This_DEMP
compares_VPRT
with_PIN
a_DT
decrease_NN
in_PIN
the_DT
FTSE_NN
100_CD
Payable_JJ
3rd_CD
July_NN
2003_CD
index_NN
of_PIN
24_CD
per_PIN
cent_NN
during_PIN
the_DT
year_NN
._.
In_PIN
the_DT
two_CD
years_NN
since_OSUB
the_DT
merger_NN
,_,
the_DT
share_NN
price_NN
has_VPRT [PEAS]
declined_VBN
by_PIN
37_CD
per_PIN
cent_NN
from_PIN
18.90_CD
Second_JJ
quarter_NN
2003_CD
at_PIN
1st_CD
January_NN
2001_CD
which_WDT
is_VPRT [BEMA]
in_PIN
line_NN
with_PIN
a_DT
similar_JJ
decrease_NN
in_PIN
the_DT
Ex-dividend_NN
date_NN
30th_JJ
July_NN
2003_CD
FTSE_NN
100_CD
index_NN
over_IN
the_DT
same_JJ
period_NN
._.
Record_NN
date_NN
1st_CD
August_NN
2003_CD
Payable_JJ
2nd_JJ
October_NN
2003_CD
Market_NN
capitalization_NOMZ
The_DT
market_NN
capitalization_NOMZ
of_PIN
GlaxoSmithKline_NN
at_PIN
31st_CD
December_NN
Third_NN
quarter_NN
2003_CD
2002_CD
was_VBD [BEMA]
72_CD
billion_CD
._.
At_PIN
that_DEMO
date_NN
GlaxoSmithKline_NN
was_VBD [BEMA]
the_DT
third_JJ
Ex-dividend_NN
date_NN
29th_JJ
October_NN
2003_CD
largest_JJ
company_NN
by_PIN
market_NN
capitalization_NOMZ
on_PIN
the_DT
FTSE_NN
index_NN
._.
Record_NN
date_NN
31st_CD
October_NN
2003_CD
Payable_JJ
6th_JJ
January_NN
2004_CD
SmithKline_NN
Beecham_NN
plc_NN
Floating_VBG [WZPRES]
Rate_NN
Unsecured_NN
Loan_NN
Stock_NN
1990_CD
2010_CD
The_DT
loan_NN
stock_NN
is_VPRT [PASS]
not_XX0
listed_VBN
on_PIN
any_QUAN
exchange_NN
but_CC
holders_NN
may_POMD
require_VB [SUAV]
SmithKline_NN
Beecham_NN
plc_NN
to_TO
redeem_VB
their_TPP3
loan_NN
stock_NN
at_PIN
par_NN
,_,
i._FW
e._FW
1_CD
for_PIN
every_QUAN
1_CD
of_PIN
loan_NN
stock_NN
held_VBN [PRIV]
,_,
on_PIN
the_DT
first_JJ
business_NOMZ
day_NN
of_PIN
March_NN
,_,
June_NN
,_,
September_NN
and_PHC
December_NN
._.
Holders_NN
wishing_VBG [WZPRES]
to_TO
redeem_VB
all_QUAN
or_CC
part_NN
of_PIN
their_TPP3
loan_NN
stock_NN
should_NEMD
complete_VB
the_DT
notice_NN
on_PIN
the_DT
back_NN
of_PIN
their_TPP3
loan_NN
stock_NN
certificate_NN
and_CC
return_VB
it_PIT
to_PIN
the_DT
registrar_NN
,_,
to_TO
arrive_VB
at_PIN
least_JJ
30_CD
days_NN
before_IN
the_DT
relevant_JJ
redemption_NOMZ
date_NN
._.
